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212Objective: The study objective was to determine the association between preoperative B-type natriuretic
peptide levels and outcome after total cavopulmonary connection. Surgical palliation of univentricular cardiac
defects requires a series of staged operations, ending in a total cavopulmonary connection. Although outcomes
have improved, there remains an unpredictable risk of early total cavopulmonary connection takedown.
The prediction of adverse postoperative outcomes is imprecise, despite an extensive preoperative evaluation.
Methods:We prospectively enrolled 50 patients undergoing total cavopulmonary connection.We collected pre-
operative clinical data, preoperative plasma B-type natriuretic peptide levels, and postoperative outcomes,
including the incidence of an adverse outcome within 1 year of surgery (defined as death, total cavopulmonary
connection takedown, or the need for cardiac transplantation).
Results:Themean age of patients was 4.7 years (standard deviation, 2.1 years). Themedian (interquartile range)
preoperative B-type natriuretic peptide levels were higher in patients who required total cavopulmonary connec-
tion takedown and early postoperative mechanical cardiac support (n ¼ 3; median, 55; interquartile range,
42-121) compared with those with a good outcome (n ¼ 47; median, 11; interquartile range, 5-17) (P<.05).
A preoperative B-type natriuretic peptide level of 40 pg/mL or greater was highly associated with the need
for total cavopulmonary connection takedown (sensitivity, 100%; specificity, 93%; P<.05), yielding a positive
predictive value of 50% and a negative predictive value of 100%. Higher preoperative B-type natriuretic peptide
levels also were associated with longer intensive care unit length of stay, longer hospital length of stay, and
increased incidence of low cardiac output syndrome (P<.05).
Conclusions: Preoperative B-type natriuretic peptide blood levels are uniquely associated with the need for
mechanical support early after total cavopulmonary connection and total cavopulmonary connection takedown,
and thus may provide important information in addition to the standard preoperative assessment. (J Thorac Car-
diovasc Surg 2014;148:212-9)The total cavopulmonary connection (TCPC) is the surgical
procedure of choice for suitable patients with a variety of
univentricular or nonseptable hearts. After the TCPC, there
is no subpulmonary ventricle between the systemic venous
return and the pulmonary circulation. The disadvantages of
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The Journal of Thoracic and Cardiovascular Surgmismatch, absence of right ventricular to pulmonary artery
coupling, and systemic venous return, which is dependent
on gravity and respiratory-driven forces. This circulation
lacks adaptability and often fails in the setting of increased
pulmonary vascular resistance (PVR), valvular dysfunction,
or decreased ventricular performance.1-5 Although
mortality after TCPC is low with careful patient selection,
the accurate prediction of adverse postoperative outcomes
is difficult, and there remains an unpredictable risk of
early and late TCPC takedown.
B-type natriuretic peptide (BNP) is a 32-amino acid
polypeptide hormone secreted by the myocardium in
response to various stimuli that has natriuretic, diuretic,
and vasoactive properties.6,7 Recent studies demonstrated
that perioperative changes in BNP levels may predict
postoperative morbidity and mortality after surgery for the
repair or palliation of congenital cardiac defects.8-12
However, the potential utility of preoperative BNP levels
as predictors of postoperative outcomes in patients
undergoing a TCPC has not been investigated.
We hypothesized that preoperative BNP levels would be
associated with unexpected outcomes after TCPC inery c July 2014
Abbreviations and Acronyms
AV ¼ atrioventricular
BNP ¼ B-type natriuretic peptide
CPB ¼ cardiopulmonary bypass
ECLS ¼ extracorporeal life support
ICU ¼ intensive care unit
LCOS ¼ low cardiac output syndrome
LOS ¼ length of stay
PCICU ¼ pediatric cardiac intensive care unit
PVR ¼ pulmonary vascular resistance
TCPC ¼ total cavopulmonary connection
Radman et al Congenital Heart Diseasepatients otherwise deemed to be suitable operative candi-
dates on the basis of standard preoperative clinical, echocar-
diographic, and hemodynamic assessments. Therefore, the
objectives of this study were (1) to determine preoperative
BNP levels in children undergoing TCPC and (2) investi-
gate the association between preoperative BNP levels and
postoperative outcomes.C
H
DMATERIALS AND METHODS
Design and Subjects
We conducted a prospective cohort study in the pediatric cardiac inten-
sive care unit (PCICU) at the University of California, San Francisco Chil-
dren’s Hospital from July 2005 to July 2006, April 2008 to July 2010, and
June 2011 to July 2012 (n ¼ 45) and the PCICU at Lucille Packard Chil-
dren’s Hospital from January 2012 to June 2012 (n ¼ 6). During these
time periods, parents of all eligible patients were approached for informed
consent and study enrollment. Eligible subjects included all children aged
less than 18 years undergoing TCPC. The preoperative anesthesia manage-
ment, intraoperative surgical strategy, and subsequent PCICUmanagement
followed standard institutional practices. In general, a preoperative deci-
sion to use a fenestration was based on the following criteria that would
characterize the patient as ‘‘higher risk’’: depressed ventricular function,
modestly increased PVR, pulmonary parenchymal disease or lung hypopla-
sia, and the need to perform additional procedures that would require a pro-
longed cardiopulmonary bypass (CPB) time. A perioperative decision to
perform a fenestration was made for an elevated Fontan pressure or poor
hemodynamics on emergence from CPB. The surgical and medical teams
involved in themanagement of the patients were blinded to the BNP values.
Informed consent from the patients’ parents or guardians was obtained
before enrollment in the study. The University of California, San Francisco
and the Lucille Packard Children’s Hospital review boards approved the
study.
Predictor Variables
We collected all available preoperative clinical data, including patient
demographics and preoperative hemodynamic data obtained at the time
of cardiac catheterization, including the ratio of pulmonary blood to sys-
temic blood flow, PVR, mean pulmonary artery pressure, cardiac index,
presence or absence of atrioventricular (AV) valvular regurgitation, and
systemic ventricular end-diastolic pressure, and echocardiographic reports
of ventricular function and AV valve regurgitation.
Blood samples were obtained from a venous or arterial catheter less than
24 hours preoperatively. The samples were placed immediately on ice in
chilled ethylenediamine tetraacetic acid–treated tubes. Whole blood was
used immediately to measure BNP levels using a commercially availableThe Journal of Thoracic and Cafluorescence immunoassay (Triage Meter Plus, Biosite Diagnostic, San
Diego, Calif). The measurable range of BNP on this device is between 5
and 5000 pg/mL. The estimated coefficient of variation for the assay is
9.2% to 11.4%.
Outcome Variables
The primary end point was TCPC failurewithin 1 year of surgery. TCPC
failurewas defined as death or the need for TCPC takedown or cardiac trans-
plantation. Secondary end points were the (1) duration of mechanical venti-
lation, (2) intensive care unit (ICU) length of stay (LOS), (3) hospital LOS,
and (4) development of low cardiac output syndrome (LCOS) within 48
hours after surgery. The definition of LCOS was derived from criteria pub-
lished by Hoffman,13 which included a combination of changes in clinical
signs and biochemical indicators. Specifically, LCOS criteria includes
tachycardia, oliguria, poor perfusion, cardiac arrest, or metabolic acidosis,
and the need for interventions aimed at augmenting cardiac output, such as
increased pharmacologic support relative to the baseline and cardiac pacing.
Postoperative clinical and hemodynamic data were collected daily by an
observer blinded to the BNP results, including the following: mean sys-
temic arterial pressure, common atrial pressure, and heart rate on admission
to the ICU, postoperative ICU and hospital LOS, time to chest tube removal
and chest tube output, pleural effusions on chest x-ray, biochemical evi-
dence of chylothorax, occurrence of LCOS, and duration of mechanical
ventilation. Postoperative biochemical data collected included hematocrit,
arterial and venous blood gases, serum lactate, blood urea nitrogen, and
creatinine on admission to the ICU.
Data Collection and Management
Study data were collected prospectively and managed using REDCap
(Research Electronic Data Capture) electronic data capture tools hosted
at University of California at San Francisco.14 REDCap is a secure web-
based application designed to support data capture for research studies,
providing (1) an interface for validated data entry; (2) audit trails for
tracking data manipulation and export procedures; (3) automated export
procedures for data downloads to common statistical packages; and (4) pro-
cedures for importing data from external sources.
Statistical Analysis
We analyzed group differences using the t test for parametric data and
the Wilcoxon rank-sum test for nonparametric data. We used simple and
multivariate logistic regression to explore correlations between the contin-
uous predictor variable (BNP) and the binary outcome variables (good/
adverse outcome and incidence of LCOS). Next, we fit linear regression
models to study correlations between the continuous predictor variable
(BNP) and the continuous clinical outcome variables (ICU LOS, hospital
LOS, and duration of mechanical ventilation). However, considering the
general rule of thumb in formal regression methods is to use only 1 covar-
iate per every 10 outcomes, the rarity of the outcome being studied (n¼ 3)
made meaningful interpretation of our exploratory models unreasonable.15
Statistical analyses were performed using Stata 12 (StataCorp LP, College
Station, Tex).RESULTS
Subjects
We enrolled 51 patients undergoing TCPC. One patient
did not undergo TCPC at the time of surgery and was
excluding from the analysis. All remaining patients had
an extracardiac conduit placed between the inferior vena
cava and the pulmonary artery, 26 of which were fenes-
trated. All patients had a cardiac catheterization performed
within 3 months before surgery. The patients’rdiovascular Surgery c Volume 148, Number 1 213
TABLE 1. Preoperative characteristics
Age (y) 4.7  2.1
Weight (kg) 16.1  6.0
Male, n (%) 30 (60)
Type of cardiac lesion, n (%)
HLHS 23 (46)
Tricuspid atresia 7 (14)
DORV 7 (14)
Unbalanced AVSD 6 (12)
PA-IVS 4 (8)
DILV 1 (2)
TGA-VSD-PS 1 (2)
Ebstein’s anomaly-HRV 1 (2)
Preoperative hemodynamic data
Heart rate (beats/min) 103  15
Mean arterial pressure (mm Hg) 77  12
Arterial oxygen saturation (%) 83  6
Qp:Qs 0.73  0.26
PVR (Wood’s units) 2.0  0.9
mPAP (mm Hg) 11  3
CI (L/min/m2) 3.5  1.2
SVEDP (mm Hg) 8  4
Data are presented as mean  standard deviation. AVSD, Atrioventricular septal
defect; CI, cardiac index; DILV, double inlet left ventricle; DORV, double outlet right
ventricle; HLHS, hypoplastic left heart syndrome; HRV, hypoplastic right ventricle;
mPAP,mean pulmonary artery pressure; PA-IVS, pulmonary atresia-intact ventricular
septum; PS, pulmonary stenosis; PVR, pulmonary vascular resistance;Qp/Qs, ratio of
pulmonary blood flow over systemic blood flow; SVEDP, systemic ventricular
end-diastolic pressure; TGA, transposition of great arteries; VSD, ventricular septal
defect.
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namic data are shown in Table 1.Outcomes
Primary end points. Three patients (6%) had an adverse
outcome. The preoperative diagnoses, surgical details, and
specific postoperative events classifying the adverse out-
comes are shown in Table 2. All 3 patients with adverseTABLE 2. Diagnoses and specific postoperative events of patients with ad
Patient Surgery D
1 TCPC extracardiac and fenestrated, and L pulmonary
artery plasty
HLHS
2 TCPC extracardiac and fenestrated, and R atrial
maze, R atrial reduction, and oversew of
pulmonary valve
Ebstein’
3 TCPC extracardiac and fenestrated, and focalization
of hepatic veins
Unbalan
AVSD,Atrioventricular septal defect;CPB, cardiopulmonary bypass; ECLS, extracorporeal
LCOS, low cardiac output syndrome; LOS, length of stay; MBTS, modified Blalock–T
PLE, protein-losing enteropathy; POD, postoperative day; TCPC, total cavopulmonary co
214 The Journal of Thoracic and Cardiovascular Surgoutcome underwent additional procedures at the time of
the Fontan (Table 2). Seven patients (15%) with good
outcome underwent additional procedures at the time of
the Fontan. These procedures included pulmonary artery
reconstruction (n ¼ 4), repair of right ventricular outflow
tract aneurysm (n¼ 1), repair of AV valve (n¼ 1), and cor-
onary artery bypass graft with left internal thoracic artery to
left anterior descending coronary artery (n ¼ 1).
No enrolled patients died or required cardiac transplanta-
tion during the study period. Patients with an adverse post-
operative outcome were older and weighed more (Table 3).
The presence or absence of AV valve regurgitation and pre-
operative hemodynamic indices did not differ between pa-
tients undergoing TCPC with and without an adverse
outcome (Table 3). Use of aortic crossclamping was not
significantly associated with preoperative BNP levels. On
return to the PCICU after surgery, first recorded heart
rate, common atrial pressure, serum creatinine, and serum
lactate were higher in patients receiving TCPC with adverse
outcomes, whereas arterial oxygen saturations were lower
(Table 3).
Secondary end points. The median (interquartile range)
duration of mechanical ventilation was 8 (7-12) hours in pa-
tients who underwent TCPC. LCOS developed in 8 patients
(16%) within the first 48 hours after surgery. The median
(interquartile range) ICU LOS and hospital LOS were 5
(4-9) days and 14 (10-22) days, respectively. Age, gender,
and preoperative hemodynamic data obtained from cardiac
catheterizations were not associated with any secondary
outcomes. Patients with adverse outcomes had a higher
incidence of LCOS and longer ICU LOS (Table 3).Preoperative B-Type Natriuretic Peptide Levels and
Outcomes
Preoperative BNP levels were greater in patients who
required TCPC takedown than in patients with a goodverse outcome
iagnosis Outcome
Fontan circulation taken down after return to the OR
on POD 1 because of failed Fontan circulation.
Unable to separate from CPB; placed on ECLS.
s anomaly-HRV Fontan circulation taken down in the OR because of
failed Fontan circulation, unable to separate from
CPB; another MBTS was added in the same
operation.
ced AVSD Fontan circulation taken down 11 mo after operation
because of poor hemodynamics requiring
prolonged and frequent PCICU hospitalizations
and the ultimate development of PLE; also had
ECLS during the postoperative course of TCPC
because of profound LCOS at PODs 2-5.
life support;HLHS, hypoplastic left heart syndrome;HRV, hypoplastic right ventricle;
aussig shunt; OR, operating room; PCICU, pediatric cardiac intensive care unit;
nnection.
ery c July 2014
TABLE 3. Characteristics of patients undergoing total cavopulmonary anastomosis with good postoperative outcome or adverse outcome
Patient characteristics Good outcome Adverse outcome P
N (%) 47 (94) 3 (6)
Age (y) 4.5  1.9 7.2  4.1 .028
Weight (kg) 15.7  5.3 23.0  12.2 .039
Male, n (%) 27 (57) 3 (100) .151
Preoperative BNP level (pg/mL) 11 (5-17) 55 (42, 55, 121) .007
Use of CPB, n (%) 34 (72) 3 (100) .299
Duration of CPB (min) 54 (42-86) 80 (63, 80, 96) .260
Use of aortic crossclamp, n (%) 6 (13) 2 (67) .013
Duration of aortic crossclamp (min) 31 (19-42) 44 (44-44) .480
Fenestration, n (%) 23 (49) 3 (100) .096
Extracardiac conduit, n (%) 47 (100) 3 (100)
Glenn before Fontan, n (%) 43 (91) 3 (100) .797
Preoperative hemodynamic and laboratory data
Mean arterial pressure (mm Hg) 77  12 78  5 .809
Arterial oxygen saturation (%) 83  6 83  4 .839
AV valve regurgitation , n (%) 19 (40) 2 (67) .382
Qp:Qs 0.72  0.26 0.80  0.30 .623
PVR (Wood’s units) 2.0  1.0 2.1  0.6 .779
mPAP (mm Hg) 11  3 10  3 .607
CI (L/min/m2) 3.5  1.2 2.8  0.3 .322
SVEDP (mm Hg) 8  4 9  2 .848
Serum creatinine (mg/dL) 0.42  0.08 0.55  0.21 .048
Creatinine clearance 99  24 114  45 .336
Initial postoperative data on return to PCICU
Heart rate (beats/min) 119  18 152  11 .002
Arterial oxygen saturation (%) 92  8 81  13 .023
Mean arterial pressure (mm Hg) 75  11 70  15 .446
Common atrial pressure (mm Hg) 7  4 15  5 .005
Serum creatinine (mg/dL) 0.52  0.24 1.1  0.32 .001
Creatinine clearance 83  23 51  23 .022
Serum lactate (mmol/L) 2.8  1.8 5.6  2.5 .016
Outcomes
LCOS, n (%) 5 (11) 3 (100) .000
ICU LOS (d) 5 (4-8) 11 (8, 11, 56) .037
Hospital LOS (d) 14 (10-21) 36 (14, 36, 64) .079
Duration of mechanical ventilation (h) 9 (7-12) 7 (7, 7, 24) .850
Duration of chest tubes (d) 8 (5-14) 9 (8, 9, 19) .414
Bold indicates statistically significant P values (P<.05). For the good outcome group (n¼ 47), data are presented as mean standard deviation and median (interquartile range).
For the adverse outcome group (n ¼ 3), data are presented as mean  standard deviation and median (individual values). Creatinine clearance was estimated using the Shull
formula. AV, Atrioventricular; BNP, B-type natriuretic peptide; CI, cardiac index; CPB, cardiopulmonary bypass; ICU, intensive care unit; LCOS, low cardiac output syndrome;
LOS, length of stay; mPAP,mean pulmonary artery pressure; PCICU, pediatric cardiac intensive care unit; PVR, pulmonary vascular resistance;Qp/Qs, ratio of pulmonary blood
flow over systemic blood flow; SVEDP, systemic ventricular end-diastolic pressure.
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Doutcome (Figure 1, Table 3). Preoperative BNP levels
were not associated with duration of mechanical ventila-
tion. Preoperative BNP levels correlated with incidence
of LCOS and ICU LOS. There was a trend toward longer
hospital LOS with higher preoperative BNP levels
(P ¼ .079). There was no association between preopera-
tive BNP levels and age or gender. Preoperative
BNP levels did not correlate with preoperative ratio of
pulmonary blood to systemic blood flow, PVR, mean
pulmonary artery pressure, cardiac index, systemic ven-
tricular end-diastolic pressure, mean arterial pressure,
heart rate, arterial oxygen saturation, presence orThe Journal of Thoracic and Caabsence of AV valve regurgitation, or postoperative
serum lactate.
We used receiver operating characteristic curves to eval-
uate the association between various cutoff values of preop-
erative BNP and adverse outcome and incidence of LCOS.
A preoperative BNP cutoff value of 40 pg/mL was highly
associated with adverse outcome, giving a sensitivity of
100% and a specificity of 93% (area under the curve,
0.96, 95% confidence interval, 0.91-1.0) (Figure 2). These
results yield a positive predictive value of 50% and a nega-
tive predictive value of 100%. Because a preoperative BNP
level of 40 pg/mL or greater was strongly associated withrdiovascular Surgery c Volume 148, Number 1 215
FIGURE1. Preoperative BNP levels are higher in patients with adverse
outcome in the early postoperative period after TCPC. Comparisons of
preoperative BNP levels between patients with a good outcome
(n ¼ 47) and an adverse outcome (n ¼ 3) after TCPC. Horizontal lines
represent median values, and interquartile ranges are represented
with shaded boxes. An adverse outcome is defined as a failed
TCPC requiring an intervention within 12 months of the original proce-
dure. BNP, B-type natriuretic peptide; TCPC, total cavopulmonary
connection.
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Dadverse outcome, we dichotomized patients by BNP levels
of less than 40 pg/mL or 40 pg/mL or greater. The charac-
teristics of patients with a preoperative BNP level less than
40 pg/mL and 40 pg/mL or greater are shown in Table 4. Pa-
tients with a preoperative BNP level 40 pg/mL or greater
had a greater incidence of LCOS and a longer ICU and hos-
pital LOS than patients with a preoperative BNP level less
than 40 pg/mL (Table 4). Among the 47 patients with
good outcomes, no differences were identified between
the 3 patients with a preoperative BNP 40 pg/mL or greater
and the 44 patients with a preoperative BNP less than 40
pg/mL (data not shown).
One patient enrolled was excluded from the analysis after
an intraoperative decision was made to not proceed with the
TCPC because of the concern for severe A-V valve regurgi-
tation that was underestimated during the preoperativeFIGURE 2. Preoperative BNP levels 40 pg/mL or greater are highly asso-
ciated with adverse outcome after TCPC (sensitivity, 100%; specificity,
93%; area under the curve, 0.96; 95% CI, 0.91-1.0). ROC, Receiver
operating curve.
216 The Journal of Thoracic and Cardiovascular Surgevaluation. Of note, this patient had a preoperative BNP
level of 120 pg/mL.
DISCUSSION
Outcomes after TCPC have improved markedly since
1971, when the Fontan procedure was first described.16
However, the incidence of early mortality after TCPC re-
mains between 3% and 8%. Likewise, long-term mortality
is estimated to be as high as 10%, 14%, and 18% at 5, 10,
and 15 years, respectively.2,3,17-19 Contemporary risk
factors for early and late adverse outcomes after Fontan-
type operations include impaired preoperative ventricular
function, increased pulmonary artery pressures, and a com-
mon AV valve.3,18,19 In a pilot study, we found that
preoperative BNP levels were higher in patients with
adverse outcome after TCPC than in patients with good
outcomes and that standard preoperative data were not
significantly different between these 2 groups.9 Therefore,
in the current study we expanded our initial study to test
the hypothesis that preoperative BNP blood levels are asso-
ciated with early adverse outcome after TCPC. We found
that a BNP level greater than 40 pg/mL was highly associ-
ated with the need for early postoperative extracorporeal
life support (ECLS) or TCPC takedown. Of note, we have
shown that in low-risk patients selected to undergo TCPC
on the basis of favorable preoperative hemodynamic assess-
ments, BNP levels better discriminate outcome after TCPC
than preoperative cardiac catheterization measurements.
This is a meaningful finding because the exact preoperative
hemodynamics that predict TCPC takedown remain elusive
and suggest that measurement of BNP blood levels may be
important in the preoperative evaluation.20
BNP is a hormone released by the myocardium that
has natriuretic, diuretic, and vasoactive properties.6,7
Produced predominantly in ventricular tissue, BNP has
emerged as a powerful biomarker of impaired myocardial
performance and has become an established aid in the
diagnosis, prognosis, and treatment of a variety of
cardiovascular disease states.8,10-12 Its use in congenital
heart disease is emerging, and recent studies demonstrate
that perioperative BNP changes may predict outcomes in
an age- and lesion-specific fashion, including partial cavo-
pulmonary connections for single ventricular heart disease.9
However, previous studies in congenital heart disease did
not demonstrate associations between outcomes and preop-
erative levels, only perioperative changes.8-12,21 In our
previous study examining perioperative BNP levels in
patients undergoing partial cavopulmonary connections
and TCPC, we found that preoperative BNP levels were
higher in 2 patients with poor outcome after TCPC
compared with 9 patients with good outcome after TCPC.
With a 5-fold higher sample size, the present study confirms
this preliminary finding and to our knowledge is the first to
robustly demonstrate the association between a singleery c July 2014
TABLE 4. Characteristics of patients undergoing total cavopulmonary anastomosis with preoperative B-type natriuretic peptide level<40 pg/mL
or 40 pg/mL
Patient characteristics Preoperative BNP level<40 pg/mL Preoperative BNP level 40 pg/mL P
N (%) 44 (88) 6 (12)
Age (y) 4.6  2.0 5.0  2.9 .618
Weight (kg) 15.8  5.6 18.0  7.9 .333
Male, n (%) 25 (57) 5 (83) .086
Use of CPB, n (%) 31 (70) 6 (100) .118
Duration of CPB (min) 55 (42-90) 63 (52-96) .423
Use of aortic crossclamp, n (%) 6 (14) 2 (33) .225
Duration of aortic crossclamp (min) 31 (19-42) 44 (44-44) .480
Fenestration, n (%) 22 (50) 4 (67) .486
Extracardiac conduit, n (%) 44 (100) 6 (100)
Glenn before Fontan, n (%) 40 (91) 6 (100) .707
Preoperative hemodynamic and laboratory data
Mean arterial pressure (mm Hg) 77  13 76  8 .854
AV valve regurgitation, n (%) 16 (36) 5 (83) .982
Arterial oxygen saturation (%)* 84  6 82  6 .502
Qp:Qs 0.71  0.26 0.84  0.27 .191
PVR (Wood’s units) 2.0  0.9 2.1  1.4 .618
mPAP (mm Hg) 11  3 11  2 .812
CI (L/min/m2) 3.5  1.2 3.0  0.4 .281
SVEDP (mm Hg) 8  4 9  1 .556
Serum creatinine (mg/dL) 0.42  0.08 0.47  0.15 .278
Creatinine clearance 98  24 112  31 .231
Initial postoperative data on return to PCICU
Heart rate (beats/min) 119  18 134  21 .041
Arterial oxygen saturation (%) 92  8 87  11 .133
Mean arterial pressure (mm Hg) 75  10 73  17 .708
Common atrial pressure (mm Hg) 7  4 12  5 .019
Serum creatinine (mg/dL) 0.50  0.16 0.83  0.50 .001
Creatinine clearance 83  23 69  27 .202
Serum lactate (mmol/L) 2.8  1.9 3.9  2.0 .126
Outcomes
Adverse outcome, n (%) 0 3 (50) .000
LCOS, n (%) 2 (5) 6 (100) .000
ICU LOS (d) 5 (4-8) 8 (6-18) .020
Hospital LOS (d) 12 (10-19) 22 (15-34) .020
Duration of mechanical ventilation (h) 9 (7-12) 7 (7-17) .286
Duration of chest tubes (d) 8 (5-13) 10 (7-17) .392
Bold indicates statistically significant P values (P<.05). Data are presented as mean standard deviation and median (interquartile range). Creatinine clearance was estimated
using the Shull formula. AV, Atrioventricular; BNP, B-type natriuretic peptide; CI, cardiac index; CPB, cardiopulmonary bypass; ICU, intensive care unit; LCOS, low cardiac
output syndrome; LOS, length of stay; mPAP, mean pulmonary artery pressure; PCICU, pediatric cardiac intensive care unit; PVR, pulmonary vascular resistance; Qp/Qs, ratio
of pulmonary blood flow over systemic blood flow; SVEDP, systemic ventricular end-diastolic pressure. *Postoperative arterial saturations were significantly higher among the
nonfenestrated Fontans compared with those with fenestrations: 94  8 versus 88  8, P ¼ .016.
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patients undergoing surgery for congenital heart disease.
Although our findings demonstrate the association be-
tween an increased preoperative BNP level and poor post-
operative outcome in patients undergoing TCPC, the
potential mechanisms, particularly at a relatively low cutoff
value (40 mg/dL), are unclear. The regulation of the produc-
tion and release of BNP is not entirely understood, because
it depends on multiple, often opposing, factors.10,11,22,23
Factors known to increase BNP expression and release
include increased ventricular wall stress (pressure andThe Journal of Thoracic and Cavolume), hypoxia, increased central blood volume, and
neuroendocrine mechanisms.7 Of note, in patients with sin-
gle ventricular physiology, Law and colleagues24 demon-
strated an elevation in BNP levels in patients with
ventricular failure, independently of cavopulmonary fail-
ure. We speculate that in the preoperative TCPC setting,
BNP values may reflect important clinical parameters in
ventricular performance not captured by our current routine
evaluations. This requires further investigation.
Potential alterations in BNP expression, release, and
clearance in the setting of abnormal cardiac developmentrdiovascular Surgery c Volume 148, Number 1 217
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Dare unknown. Our results demonstrate that a relatively low
preoperative BNP cutoff level (>40 pg/mL) is associated
with adverse outcome after TCPC. This is significantly
lower than the cutoff levels first established for the diag-
nosis of congestive heart failure in adults25,26 but is
concordant with 2 previously published studies that
showed that a threshold value of greater than 30 to 45 pg/
mL showed both sensitivity and specificity for predicting
heart failure in children with a single cardiac ventricle.
This cutoff level is also greater than published values in
similarly aged normal children (5.1-12.1 pg/mL).27,28
Further, our relatively low BNP cutoff level fits with the
results of the Pediatric Heart Network Fontan cross-
sectional study that demonstrated normal BNP levels in
the majority of ambulatory patients undergoing the Fontan
(median time from Fontan, 8.2 years), but higher BNP
levels in patients with pre-Fontan systolic dysfunction and
in patients with late post-Fontan complications.21
Study Limitations
There are several limitations to this investigation that
warrant discussion. Most notable is the relatively small
sample size, which was associated with a heterogeneous
group of anatomic lesions and the use of both fenestrated
and nonfenestrated surgical techniques. The small sample
size makes it difficult to conclude that BNP is a true predic-
tor of adverse outcome after TCPC. However, there is a
clear association between increased preoperative BNP
levels and adverse postoperative outcome in this unique
population. Further, this precludes our ability to demon-
strate potential interactions between preoperative BNP
levels and outcomes in subjects with specific cardiac lesions
after the TCPC. In addition, all 3 patients experiencing
adverse outcome underwent additional procedures at the
time of the Fontan compared with 15% of the group with
good outcome. Although there were no significant differ-
ences in the duration of CPB time or aortic crossclamp
time as a result, it is challenging to determine whether these
additional procedures played a role in the observed out-
comes. Last, our study was undertaken only in children
considered eligible for a TCPC. Because we have no data
on higher-risk patients (ie, those excluded from TCPC after
standard assessment), the associations demonstrated be-
tween preoperative BNP and outcomes are applicable
only to patients undergoing the Fontan with favorable pre-
operative hemodynamics.
Because of the robust nature of the data, we are confident
that the results are not due to type I error. However, a small
possibility of this always exists in pilot studies with small
sample sizes such as this. In addition, the enrolled patients
were from 2 high-volume pediatric cardiothoracic surgery
centers, with the obligate subtle differences in surgical
approach/technique and postoperative management. Of
note, the strength of the association between postoperative218 The Journal of Thoracic and Cardiovascular Surgoutcome and a BNP cutoff level greater than 40 pg/mL
was sustained despite a small sample size from 2 centers,
suggesting it is a robust measurement.CONCLUSIONS
We found that preoperative BNP levels are strongly asso-
ciated with the need for ECLS and TCPC takedown in the
early postoperative period after TCPC. Specifically, we
found that a value greater than 40 pg/mL was highly sensi-
tive and specific in its association with TCPC takedown
within 12 months of surgery, the need for ECLS, and pro-
longed ICU and hospital LOS. Large multicentered studies
are needed to definitively establish the predictive value of
BNP blood levels in the management of patients after
TCPC and to overcome the limitations of the present study.
However, our current results suggest that preoperative BNP
levels have the potential to uniquely predict early outcome
after TCPC and thus, after validation in a larger TCPC
cohort, should be considered for inclusion in the standard
assessment of candidates for a Fontan-type operation.
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